#diversimmune

Abpro Announces Partnership and Investment with Essex Bio for Development of Antibody Therapeutics

APRIL 6, 2016

Abpro, a Massachusetts-based integrated life science company at the forefront of synthetic biology, has announced a partnership with Essex Bio, a biopharmaceutical company based in China. It has been agreed that Abpro and Essex will jointly develop multiple monoclonal antibodies in ophthalmology and immuno-oncology by leveraging the DiversImmune™ platform of Abpro. Moreover, as part…